Several receptor tyrosine kinase inhibitors (RTKIs) have been reported to interact strongly with ABCB1 and/or ABCG2 and reverse multidrug resistance in cancer cells overexpressing ABCB1 and/or ABCG2 [17,18,29]. The gene discussed is NTRK1; the disease is cancer.